Levodropropizine Oral Liquid (Commercial)

Levodropropizine Oral Liquid (Commercial)
Product Description

A complementary liquid presentation associated with the symptomatic relief of dry cough.

Dosage form: Oral liquid Strength: 6 mg/ml Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier status: Available Together, the tablet and oral liquid presentations allow partners to consider a broader Levodropropizine portfolio with two distinct dosage forms.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Specifications
  • Details
    A complementary liquid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Oral liquid Strength: 6 mg/ml Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier status: Available Together, the tablet and oral liquid presentations allow partners to consider a broader Levodropropizine portfolio with two distinct dosage forms.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist

More Products from Medis ehf. (26)

  • Empagliflozin (Pipeline)

    Product Empagliflozin (Pipeline)

    A two-strength oral pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 10 mg and 25 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Product class: Bl...
  • Enzalutamide (Pipeline)

    Product Enzalutamide (Pipeline)

    An oral oncology pipeline opportunity associated with prostate cancer.

    Dosage form: Film-coated tablet Strengths: 40 mg and 80 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Prostate cancer Product class: Endocrine th...
  • Esomeprazole Capsules (Reformulation)

    Product Esomeprazole Capsules (Reformulation)

    A gastro-resistant capsule reformulation associated with gastroesophageal reflux disease.

    Dosage form: Gastro-resistant capsule Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indication: Gastroesophageal reflux disease Product class: Peptic ulcer and gastro-oeso...
  • Esomeprazole Tablets (Commercial)

    Product Esomeprazole Tablets (Commercial)

    An established gastroenterology opportunity available in two widely recognised strengths.

    Dosage form: Gastro-resistant tablet Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indications: Duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux d...
  • Ferric Carboxymaltose (Commercial)

    Product Ferric Carboxymaltose (Commercial)

    An intravenous product opportunity for partners active in hospital care, hematology and iron-deficiency management.

    Dosage form: Solution for injection or infusion Strength: 50 mg/ml Therapeutic area: Blood and blood-forming organs Key indication: Iron-deficiency ...
  • Filgrastim (Commercial)

    Product Filgrastim (Commercial)

    A pre-filled syringe opportunity associated with supportive care and the management of neutropenia.

    Dosage form: Solution for injection in a pre-filled syringe Strengths: 30 MIU/0.5 ml and 48 MIU/0.8 ml Therapeutic area: Antineoplastic and immunomodulating agents ...
  • Levodropropizine Tablets (Commercial)

    Product Levodropropizine Tablets (Commercial)

    An oral solid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Tablet Strength: 60 mg Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier status: Available ...
  • Lisdexamfetamine (Commercial)

    Product Lisdexamfetamine (Commercial)

    A broad-strength capsule opportunity associated with attention deficit hyperactivity disorder.

    Dosage form: Hard capsule Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Therapeutic area: Nervous system Key indication: Attention deficit hyperactivity disorde...
  • Lisinopril (Reformulation)

    Product Lisinopril (Reformulation)

    A six-strength ACE-inhibitor opportunity undergoing reformulation.

    Dosage form: Film-coated tablet Strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: ACE inhibitor Expected d...
  • Losartan (Reformulation)

    Product Losartan (Reformulation)

    A four-strength angiotensin II receptor blocker opportunity undergoing reformulation.

    Dosage form: Film-coated tablet Strengths: 12.5 mg, 25 mg, 50 mg and 100 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Angiotensin II re...
  • Melatonin (Commercial)

    Product Melatonin (Commercial)

    A prolonged-release oral product associated with circadian-rhythm sleep disorders.

    Dosage form: Prolonged-release tablet Strength: 2 mg Therapeutic area: Nervous system Key indication: Circadian-rhythm sleep disorders Product class: Hypnotic and sedative a...
  • Out-licensing

    Product Out-licensing

    Medis is an established provider of dossiers and products in all areas of the world with launches and marketing authorizations in over 140 countries to date.

Medis ehf. resources (2)